XOMA Royalty Corporation (XOMAP)
| Market Cap | 710.16M +153.5% |
| Revenue (ttm) | 48.56M +13.2% |
| Net Income | 19.93M |
| EPS | 1.58 |
| Shares Out | 12.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $2.16 (8.63%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 362 |
| Open | 24.98 |
| Previous Close | n/a |
| Day's Range | 24.98 - 24.98 |
| 52-Week Range | 24.93 - 30.00 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About XOMAP
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets ... [Read more]
News
XOMA Royalty Transcript: EGM 2026
The meeting addressed three key proposals: a merger agreement, a holding company reorganization, and a compensation plan. All proposals received sufficient votes for approval, with no questions raised by shareholders. Final results will be filed with the SEC.
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash di...
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on June 12, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on June 10, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Transcript: AGM 2026
The meeting covered director elections, auditor ratification, incentive plan amendments, and executive compensation. All proposals passed with a quorum present, and no shareholder questions were raised during the session.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Quarterly report: Q1 2026
XOMA Royalty has published its Q1 2026 quarterly earnings report on May 12, 2026.
XOMA Royalty Slides: Q1 2026
XOMA Royalty has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Proxy statement: Proxy filing
XOMA Royalty filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy...
XOMA Royalty Earnings Call Transcript: Q4 2025
2025 saw strong financial growth, with royalty receipts up 68% year-over-year and positive operating cash flow enabling $16 million in share buybacks. The portfolio expanded to over 120 assets, with several late-stage catalysts expected in 2026 and a focus on disciplined capital allocation.
XOMA Royalty Annual report: Q4 2025
XOMA Royalty has published its Q4 2025 annual report on March 18, 2026.
XOMA Royalty Earnings release: Q4 2025
XOMA Royalty released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
XOMA Royalty Slides: Q4 2025
XOMA Royalty has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 18, 2026.
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up ...
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results o...
XOMA Royalty Transcript: Leerink Global Healthcare Conference 2026
Management highlighted a diversified, royalty-driven portfolio strategy, recent creative acquisitions, and ongoing litigation with J&J over Tremfya royalties. Financials show strong cash flow and low tax rates, with multiple late-stage pipeline catalysts expected in 2024 and 2027.
XOMA Royalty Transcript: TD Cowen 46th Annual Health Care Conference
The company has built a diversified royalty portfolio with over 120 assets, including 15 in phase III, and uses creative transactions to drive growth and tax efficiency. Key catalysts include multiple phase III readouts and commercial launches, with profitability expected by 2027. Strategic capital allocation and share buybacks aim to maximize shareholder value.
XOMA Royalty Slides: Corporate presentation
XOMA Royalty has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helpin...